NASDAQ$AYTU
Aytu BioScience Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Aytu BioPharma reported financial results for the fiscal third quarter ended March 31, 2021 and provided recent business highlights.
Aytu BioPharma reported a net revenue of $13.5 million for Q3 2021, compared to $8.2 million in the same quarter last year. The company's net loss was $25.5 million, or $1.41 per share, which included Neos merger-related expenses and inventory write-offs.
- Closed merger with Neos Therapeutics, creating a proforma combined $100 million revenue specialty pharmaceutical company.
- Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline
- Consumer health division revenue reached a record $8.4 million.
- Rx division revenue increased by 9% over the same quarter last year.
Headline financials
Revenue & EPS history
Aytu BioScience · Revenue · Quarterly
$13.5M
Revenue by segment
Aytu BioScience · $210K total across 1 segment · Q4 2023
- Other$210K-42.6%100.0%
Forward guidance
Aytu BioPharma anticipates several milestones and events for calendar year 2021 and 2022.
Tailwinds
- Continue discussions with the FDA and other regulatory agencies regarding the advancement of its Healight™ UVA light catheter technology.
- Initiate Phase 2 trial of Healight in COVID-19 in second half of 2021.
- Announce multiple new product launches for the consumer health segment in the second half of 2021.
- Integrate sales forces and Neos RxConnect, to be rebranded as Aytu RxConnect, in the second half of 2021.
- Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 1st and the Raymond James Human Health Innovation Conference on Wednesday, June 23rd.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-1.0%
Avg return
Earnings day
-4.9%
Avg return
5 days after
-7.0%
Avg return
30 days after
19%
12 / 64 earnings
Positive
+91.7%
Q3 2025
Best reaction
-31.0%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -0.4% | -9.7% | -4.9% | |
| Q2 2026 | -3.3% | -11.8% | -4.4% | |
| Q1 2026 | -13.1% | -2.9% | +11.7% | |
| Q4 2025 | -20.1% | -31.9% | -9.6% | |
| Q3 2025 | +91.7% | +50.4% | +44.4% | |
| Q2 2025 | -0.7% | +0.7% | -13.7% | |
| Q1 2025 | -10.9% | -8.0% | -17.2% | |
| Q4 2024 | -2.9% | -3.3% | -11.1% | |
| Q3 2024 | -10.8% | -7.2% | -14.2% | |
| Q2 2024 | +4.3% | +6.0% | -4.0% | |
| Q1 2024 | -14.2% | -14.2% | +6.7% | |
| Q4 2023 | +61.8% | +76.4% | +60.6% | |
| Q3 2023 | -12.8% | -16.6% | -24.2% | |
| Q2 2023 | -5.1% | -9.9% | -29.8% | |
| Q1 2023 | +5.3% | +21.1% | +10.5% | |
| Q4 2022 | +0.0% | +0.0% | -10.5% | |
| Q3 2022 | +5.8% | +7.7% | -5.8% | |
| Q2 2022 | +5.6% | +4.8% | -13.5% | |
| Q1 2022 | -10.5% | -18.2% | -36.0% | |
| Q4 2021 | -3.7% | -0.7% | -19.9% | |
| Q3 2021 | +0.7% | +5.0% | -5.9% | |
| Q2 2021 | -5.3% | -9.0% | -5.1% | |
| Q1 2021 | -4.9% | -8.8% | -38.4% | |
| Q4 2020 | -14.1% | -16.3% | -23.0% | |
| Q3 2020 | -7.7% | -13.0% | -13.0% | |
| Q2 2020 | +2.6% | +2.6% | +49.4% | |
| Q1 2020 | -21.7% | -28.3% | -14.2% | |
| Q4 2019 | -10.9% | -16.7% | -18.8% | |
| Q3 2019 | -6.7% | -14.8% | -21.1% | |
| Q2 2019 | -22.0% | -21.2% | +6.8% | |
| Q1 2019 | -22.0% | -21.2% | +6.8% | |
| Q4 2018 | -2.8% | -13.0% | -10.2% | |
| Q3 2018 | +24.2% | +12.1% | +21.2% | |
| Q2 2018 | -31.0% | -54.5% | -86.6% | |
| Q1 2018 | -14.8% | -22.6% | -29.0% | |
| Q4 2017 | -3.0% | +3.8% | +7.8% | |
| Q3 2017 | -4.0% | -9.3% | -6.7% | |
| Q2 2017 | -4.9% | -9.8% | -16.7% | |
| Q1 2017 | +11.6% | +5.4% | +16.1% | |
| Q4 2016 | +5.3% | +2.7% | -13.1% | |
| Q3 2016 | -3.1% | — | — | |
| Q2 2016 | +7.7% | — | — | |
| Q1 2016 | +0.0% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +0.0% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — | |
| Q4 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro